TOKYO, Apr 10 (Pulse News Wire) – Medicinova,inc. (4875.T) announced on April 9 that its annual shareholders meeting will take place on Tuesday, June 23, 2026.
The record date for determining eligible shareholders who will attend the meeting is set for Friday, April 24, 2026. Only those shareholders whose names are recorded in the final shareholder registry on the record date will be entitled to participate in the voting process at the upcoming meeting. MediciNova, headquartered in La Jolla, California, is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases, neurodegenerative disorders, and cancer.
Key compounds in development include MN-166 (ibudilast) and MN-001 (tipelustat). MN-166 is currently undergoing Phase III trials for amyotrophic lateral sclerosis (ALS) and cervical spondylotic myelopathy (CSM), while also advancing through Phase II trials for glioblastoma and substance dependence. MN-001 is being tested in Phase II trials targeting lipid abnormalities caused by diabetes and non-alcoholic fatty liver disease (NAFLD).
The company has a strong track record of conducting numerous investigator-initiated clinical trials funded by government agencies and public institutions in Europe and North America.
🟢 Confidence: High AI-translated content.